ArticleInternational journal of reproductive biomedicine2024
Magnetic graphene oxide increases the biocompatibility and nuclear factor erythroid 2-related factor 2 antioxidant of human cumulus cells: A lab-trial study.
Article in International journal of reproductive biomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although assisted reproductive technology has been improved, the success rate is only 30%. Since the interaction between oocytes and cumulus cells (CCs) is necessary for the formation of a fertile oocyte, increasing the survival rate of CCs can improve the function of oocytes in infertile women. Objective: This study aimed to investigate the effects of magnetic graphene oxide (MGO) nanocomposite on the biocompatibility and antioxidant activity of human CCs. Materials and Methods: In this lab-trial study, from July 2021-2023 human CCs were collected from 37 women aged 20-37 yr and cultured in a medium containing Dulbecco's Modified Eagle's/F12, fetal bovine serum (10%), and penicillin-streptomycin (1%). Then CCs were treated with increasing concentrations of nano-MGO for 24, 48, and 72 hr (3[4, 5-dimethylthiazole-2-yl]-2, 5-diphenyltetrazolium bromide) assay and flow cytometry technique were used to compare the survival rate and apoptosis of CCs before and after treatment. Western blot test was used for expressing nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant in 2 groups. Results: The results of the present study showed that treatment with MGO increased the viability of CCs at a concentration of 50 µg/ml after 48 hr (p Conclusion: Our results highlight the use of MGO in a new strategy that improves CCs viability and secretion of antioxidant protein Nrf2, thereby potentially increasing in vitro fertilization outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.